Stem Cell Therapeutics Graduates to the Toronto Stock Exchange
April 21 2014 - 7:00AM
Marketwired
Stem Cell Therapeutics Graduates to the Toronto Stock Exchange
Grants stock options to management
TORONTO, ONTARIO--(Marketwired - Apr 21, 2014) - Stem Cell
Therapeutics Corp. ("SCT") (TSX-VENTURE:SSS)(OTCQX:SCTPF), an
immuno-oncology company developing cancer stem cell-related
therapeutics, today announces that its common shares have been
approved for listing and will commence trading on the Toronto Stock
Exchange ("TSX") at the opening of the TSX on April 22, 2014. The
Company's common shares will continue to trade under the trading
symbol "SSS" and its common shares will be delisted from the TSX
Venture Exchange concurrent to the commencement of trading on the
TSX.
"Graduation to the TSX is one of several important corporate
milestones we aim to achieve this year as we continue to grow our
company," commented Dr. Niclas Stiernholm, CEO of SCT. "Listing on
the TSX is expected to provide the company with improved access to
the capital markets and greater recognition among healthcare
investors."
The company also announced that the Board of Directors has
granted options to purchase 7,923,868 common shares of the company
to its executive officers. The options were issued at an exercise
price of $0.345 per share for a ten-year term. The grant of options
is subject to acceptance by the TSX Venture Exchange. SCT has
approximately 344 million shares outstanding on a fully diluted
basis.
About Stem Cell Therapeutics:
Stem Cell Therapeutics Corp. (SCT) is an immuno-oncology company
advancing cancer stem cell discoveries into novel and innovative
cancer therapies. The Company has two premier preclinical programs,
SIRPaFc and a CD200 monoclonal antibody (mAb), which target two key
immunoregulatory pathways that tumor cells exploit to evade the
host immune system. SIRPaFc is an antibody-like fusion protein that
blocks the activity of CD47, a molecule that is upregulated on
cancer stem cells in AML and several other tumors. The CD200 mAb is
a fully human monoclonal antibody that blocks the activity of
CD200, an immunosuppressive molecule that is overexpressed by many
hematopoietic and solid tumors. SCT's clinical stage programs
include the recently in-licensed program focused on the structure
of tigecycline, which is currently being evaluated in a
multi-centre Phase I study in patients with acute myeloid leukemia
(AML), as well as TTI-1612, a non-cancer stem cell asset that
recently completed a 28-patient Phase I trial in interstitial
cystitis ("IC") patients. For more information, visit:
www.stemcellthera.com
Caution Regarding Forward-Looking Information:
This press release may contain forward-looking statements, which
reflect SCT's current expectation regarding future events. These
forward-looking statements involve risks and uncertainties that may
cause actual results, events or developments to be materially
different from any future results, events or developments expressed
or implied by such forward-looking statements. Such factors include
changing market conditions; the successful and timely completion of
pre-clinical and clinical studies; the establishment of corporate
alliances; the impact of competitive products and pricing; new
product development risks; uncertainties related to the regulatory
approval process or the ability to obtain drug product in
sufficient quantity or at standards acceptable to health regulatory
authorities to complete clinical trials or to meet commercial
demand; and other risks detailed from time to time in SCT's ongoing
quarterly and annual reporting. Except as required by applicable
securities laws, SCT undertakes no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Stem Cell Therapeutics Corp.James ParsonsChief Financial
Officer+1 416 595
0627jparsons@stemcellthera.comwww.stemcellthera.com
Trillium Therapeutics (NASDAQ:TRIL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Trillium Therapeutics (NASDAQ:TRIL)
Historical Stock Chart
From Apr 2023 to Apr 2024